Clinical trials: Preventive Measures
Graft Vs Host Disease
A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation
This is a Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of PRO 140 for Prophylaxis of Acute Graft-Versus-Host Disease in Patients with Acute Myeloid Leukemia (AML) or…
- Trial name
- GVHD (NCT02737306)
- Testing
- PRO 140
- Where
- 8 sites in United States
- Volunteers
- 11 people
- Sponsor
- CytoDyn, Inc.
Anthrax
BARDA Securing Anthrax Immunity For the Elderly
This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison to adults 18-50 years of age in stable…
- Trial name
- B-SAFE (NCT03518125)
- Testing
- BioThrax, AV7909
- Where
- 4 sites in United States
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Graft-Versus-Host-Disease
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis
IL-2 add-back post allogeneic hematopoietic stem cell transplant (HSCT), combined with Sirolimus (SIR), Tacrolimus (TAC) will optimize Treg reconstitution and prevent graft versus host disease (GVHD).
- Trial name
- NCT01927120
- Testing
- IL-2, Tacrolimus, Sirolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Subarachnoid Hemorrhage
Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH
Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital…
- Trial name
- DOPAST (NCT01137110)
- Testing
- Brief LEV, Extended LEV
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Washington University School of Medicine
Motavizumab Administration for a Second Season for RSV Prophylaxis
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children
The primary objective of this study was to determine the effect on immune reactivity to motavizumab (MEDI-524) of monthly intramuscular (IM) doses of motavizumab (MEDI-524) administered for a second season in children.
- Trial name
- NCT00113490
- Testing
- motavizumab (MEDI-524), palivizumab 15 mg/kg
- Where
- 6 sites in Brazil, Chile
- Volunteers
- 136 people
- Sponsor
- MedImmune LLC
Corona Virus Infection, Acute Respiratory Distress Syndrome
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Study Objective: 1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus. 2.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus
- Trial name
- COVID-19 PEP (NCT04308668)
- Testing
- Hydroxychloroquine
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,312 people
- Sponsor
- University of Minnesota
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.
- Trial name
- ARISE (NCT02483585)
- Testing
- Erenumab
- Where
- 76 sites in United States, Denmark and 6 more
- Volunteers
- 577 people
- Sponsor
- Amgen
HIV Infections, HIV/AIDS
Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP
This is a randomized clinical trial of doxycycline post-exposure prophylaxis (dPEP) to reduce bacterial STIs among Kenyan women taking pre-exposure prophylaxis (PrEP).
- Conditions
- HIV Infections, HIV/AIDS, Neisseria Gonorrheae Infection, Chlamydia Trachomatis Infection
- Trial name
- dPEP-KE (NCT04050540)
- Testing
- Doxycycline
- Where
- Kenya
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- University of Washington
Haemophilia B
A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
The study investigates how well the medicine called nonacog beta pegol (N9-GP) works in Chinese people with haemophilia B. Participants will be treated with N9-GP.
- Trial name
- Paradigm9 (NCT05365217)
- Testing
- Nonacog beta pegol
- Where
- 15 sites in China
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Infections, Meningococcal
Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study
This study will be conducted in three stages. In the DTP booster stage at 15 to 24 months of age, all subjects will receive a booster dose of Tritanrix™-HepB/Hiberix™.
- Trial name
- NCT00291343
- Testing
- Tritanrix™- HepB, Hiberix™, Mencevax™ ACWY
- Where
- 2 sites in Philippines
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Respiratory Infection, Aspergillosis
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
COVID-19 associated pulmonary aspergillosis (CAPA) is considered a potentially life-threatening infection in critically ill COVID (Corona Virus disease)-19 patients.
- Trial name
- POSACOVID (NCT05065658)
- Testing
- Posaconazole
- Where
- 3 sites in Austria, France and 1 more
- Volunteers
- 249 people
- Sponsor
- Medical University of Graz
Surgical Site Infection, Vancomycin
Pharmacokinetics of Preoperative Vancomycin
A study of plasma and tissue vancomycin pharmacokinetics in pediatric surgical patients.
- Trial name
- NCT03453684
- Testing
- Administration of Vancomycin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Colorado, Denver
Prediabetes
INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT)
This study will evaluate a VA MyHealtheVet Secure Messaging intervention that uses different intervention messaging strategies designed to increase engagement in behaviors to prevent type 2 diabetes.
- Trial name
- INVENT (NCT03403231)
- Testing
- INVENT Secure Messaging Intervention
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
The purpose of the study is to determine if participants who receive the GVHD prophylaxis medication pentostatin will have less severe hepatic toxicities than those receiving MTX.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Hodgkin's Disease
- Trial name
- NCT01188798
- Testing
- Methotrexate, Pentostatin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- St. Jude Children's Research Hospital
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV…
- Trial name
- NCT02449291
- Testing
- APD421
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 568 people
- Sponsor
- Acacia Pharma Ltd
Migraine
A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with migraine who are taking a monoclonal antibody…
- Trial name
- NCT04294147
- Testing
- Galcanezumab, Erenumab
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Congenital Bleeding Disorder, Haemophilia A
Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
This trial is conducted in China. The aim of this trial is to evaluate the clinical efficacy of turoctocog alfa in treatment of bleeding episodes in Chinese patients with severe haemophilia A (FVIII≤1%).
- Trial name
- guardian TM 7 (NCT02938585)
- Testing
- turoctocog alfa
- Where
- 11 sites in China
- Volunteers
- 68 people
- Sponsor
- Novo Nordisk A/S
Fusariosis, Onychomycosis
Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Patients admitted for autologous or allogeneic hematopoietic cell transplantation, induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid leukemia, or to receive immunosuppressive therapy…
- Trial name
- Fusarproph (NCT02714504)
- Testing
- Voriconazole or posaconazole
- Where
- Brazil
- Volunteers
- 239 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Hemophilia A
Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
The primary objective of this study is to test the feasibility of a large-scale clinical trial of once-daily prophylaxis. The secondary objectives are to collect clinical efficacy outcomes so that we can better plan a large-scale…
- Trial name
- NCT00717626
- Testing
- Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS
- Where
- 3 sites in Canada
- Volunteers
- 14 people
- Sponsor
- The Hospital for Sick Children
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard…
- Trial name
- NCT00928018
- Testing
- Sirolimus, Methotrexate, Tacrolimus
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Dana-Farber Cancer Institute